KalVista Pharmaceuticals Inc. (NASDAQ:KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch. • KalVista Pharmaceuticals stock is approaching key resistance levels. Why did KALV hit a new high?In July 2025, the U.S. Food and Drug Administration (FDA) approved Ekterly for acute attacks of hereditary angioedema (HAE) in adult and pediatric pati ...